Soon after the pictures and videos from the circuit went live, fans took to the comments section to share their views on the potential collaboration. One user said "So is this AK64 now?" Another said ...

Former Kaizer Chiefs captain Jimmy Tau has questioned the officiating in the match between Mamelodi Sundowns and Siwelele FC, during which Teboho Mokoena was shown a red card. Sundowns failed to ...

Karnataka finds itself engulfed in a tumultuous political crisis as tensions rise between Chief Minister Siddaramaiah and Deputy Chief Minister D.K. Shivakumar. This escalating feud evokes memories of ...

DK Shivakumar and K Siddaramaiah are locked in yet another power tussle in Karnataka. (File: PTI) It was well past 9 pm on May 13, 2023, when Karnataka Congress chief DK Shivakumar arrived at the ...

As suspense deepens over the Karnataka leadership crisis, Congress president Mallikarjun Kharge on Thursday said that he has called for a high-level meeting to discuss the matter and take a final ...

The political battle over Karnataka CM post has intensified between Siddaramaiah & DK Shivakumar. While Congress high command seems to be "confused", the BJP has made wildcard entry. The BJP has ...

The issue of leadership change in Karnataka has intensified in recent weeks, fueling the possibility of a prolonged battle that could further stagnate development, policy and administration.

A political power struggle is intensifying within the Karnataka Congress, focusing on a leadership crisis between Chief Minister Siddaramaiah and Deputy Chief Minister D.K. Shivakumar. Thune Breaks ...

Shiv Aroor discusses Karnataka's power tussle with BJP's Shehzad Poonawalla, Congress's Prasad Gowda & author Rasheed Kidwai. Who will Rahul back as CM-Siddaramaiah or DK Shivakumar? Five minors ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s ...